Tomáš Šálek, Iveta Andrezálová
Neuroendocrine tumours (NET) are a rare and heterogeneous group of diseases. The incidence and prevalence have been increasing over the last decades. The clinical course of patients with metastatic NETs is highly variable. The treatment has been evolving and changing in the recent years. Symptoms of hormone hypersecretion can usually be treated effectively with somatostatin analogues. Traditional therapy approaches to patients include the treatment with interferon or cytotoxic chemotherapy. In patients with progressive advanced pancreatic NET everolimus or sunitinib improves treatment results.